Interaction of homocysteine and conventional predisposing factors on risk of ischaemic stroke in young people: Consistency in phenotype-disease analysis and genotype-disease analysis

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 77, Issue 10, 2006, Pages 1150-1156

  Pezzini, Alessandro ^a   Grassi, M ^b   Del Zotto, E ^a   Assanelli, D ^c   Archetti, S ^c   Negrini, R ^c   Caimi, L ^c   Padovani, A ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); HOMOCYSTEINE;

ADULT; ARTICLE; BEHAVIOR; CEREBROVASCULAR ACCIDENT; CIGARETTE SMOKING; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE PREDISPOSITION; ENVIRONMENTAL FACTOR; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENOTYPE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR;

ADOLESCENT; ADULT; BRAIN ISCHEMIA; CAUSALITY; CEREBROVASCULAR ACCIDENT; ENVIRONMENT; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HOMOCYSTINE; HUMANS; HYPERHOMOCYSTEINEMIA; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); PHENOTYPE; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; REGISTRIES; REGRESSION ANALYSIS; RISK FACTORS;

EID: 33748995132     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2005.076083     Document Type: Article

References (29)

1. Casas PJ, Bautista LE, Smeeth L, et al. Homocysteine and stroke: evidence on a causal link from mendelian randomization. Lancet 2005;365:224-32.
2. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002;325:1202-8.
3. Kelly PJ, Rosand J, Kistler JP, et al. Homocysteine, MTHFR 677C->T polymorphism, and risk of ischemic stroke: results of a meta-analysis. Neurology 2002;59:529-36.
4. Nygard O, Vollset SE, Refsum H, et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 1995;274:1526-33.
5. Ueland PM, Refsum H, Beresford SAA, et al. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 2000;72:324-32.
6. Flossman E, Schulz UGR, Rothwell PM. Systematic review of methods and results of studies of the genetic epidemiology of ischemic stroke. Stroke 2004;35:212-27.
7. Hassan A, Markus HS. Genetics and ischaemic stroke. Brain 2000;123:1784-812.
8. Pezzini A, Del Zotto E, Archetti S, et al. Plasma homocysteine concentration, C677T MTHFR genotype and 844ins68bp CBS genotype in young adults with spontaneous cervical artery dissection and atherothrombotic stroke. Stroke 2002;33:664-9.
9. Pezzini A, Del Zotto E, Magoni M, et al. Inherited thrombophilic disorders in young adults with ischemic stroke and patent foramen ovale. Stroke 2003;34:28-33.
10. Johnson CJ, Kittner SJ, McCarter RJ, et al. Interrater reliability of an etiologic classification of ischemic stroke. Stroke 1995;26:46-51.
11. WHO Study Group on Diabetes Mellitus. World Health Organization technical report, series 727. Geneva: World Health Organization, 1985.
12. Ubbink JB, Delport R. Reference ranges for homocysteine concentrations. In: Robinson K, ed. Homocysteine and vascular disease. Dordrecht: Kluwer Academic, 2000:41-57.
13. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genetics 1995;10:111-3.
14. Agresti A. Categorical data analysis. 2nd edn. New Jersey: Wiley, 2002.
15. Breiman L, Friedman JH, Olshen RA, et al. Classification and regression trees. Belmont, CA: Wadsworth, 1984.
16. Soriente L, Coppola A, Madonna P, et al. Homozygous C677T mutation of the 5, 10 methylenetetrahydrofolate reductase gene and hyperhomocysteinemia in Italian patients with a history of early-onset ischemic stroke. Stroke 1998;29:869-71.
17. Kittner SJ, Giles WH, Macko RF, et al. Homocysteine and risk of cerebral infarction in a biracial population. The stroke prevention in young women. Stroke 1999;30:1554-60.
18. Kristensen B, Malm J, Carlberg B, et al. Epidemiology and etiology of ischemic stroke in young adults aged 18 to 44 years in Northern Sweden. Stroke 1997;28:1702-9.
19. Beccia M, Mele MC, Ferrari M, et al. Young stroke and basal and post-methionine load homocysteine and cysteine levels 1 year after the acute event: do plasma folates make the difference? Eur J Neurol 2004;11:269-75.
20. Choon-Kiat TN, Venketasubramanian N, Saw SM, et al. Hyperhomocysteinemia and risk of ischemic stroke among young Asian adults. Stroke 2002;33:1956-62.
21. Sobol AB, Bald E, Loba J. Fractions of total plasma homocysteine in patients with ischemic stroke before the age of 55 years. Angiology 2005;56:201-9.
22. Klerk M, Verhoef P, Clarke R, et al. MTHFR 677C→T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 2002;288:2023-31.
23. Russo GT, Friso S, Jacques PF, et al. Age and gender affect the relation between methylenetetrahydrofolate reductase C677T genotype and fasting plasma homocysteine concentrations in the Framingham Offspring Study Cohort. J Nutr 2003;133:3416-21.
24. Smith GD, Ebrahim S. "Mendelian randomization": can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003;32:1-22.
25. Brattstrom L, Wilken DE. Homocysteine and cardiovascular disease: cause or effect? Am J Clin Nutr 2000;72:315-23.
26. Cook NR, Zee RYL, Ridker PM. Tree and spline based association analysis of gene-gene interaction models for ischemic stroke. Stat Med 2004;23:1439-53.
27. Hassan A, Sham PC, Markus HS. Planning genetic studies in human stroke. Sample size estimates based on family history data. Neurology 2002;56:1483-8.
28. Hassan A, Markus HS. Polygenic ischemic stroke including new genetic and statistical approaches. In: Markus HS, ed. Stroke genetics. Oxford, UK: Blackwell Science, 2003:165-95.
29. The VITATOPS Trial Study Group. The VITATOPS (Vitamin To Prevent Stroke) trial: rational and design of an international, large, simple, randomised trial of homocysleine-lowering multivitamin therapy in patients with recent transient ischemic attack or stroke. Cerebrovasc Dis 2002;13:120-6.